Tracy Blusewicz, MD
Obstetrics & Gynecology · Bluffton, SCNPI 1467486456
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.2%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 63.5% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2024 at $7,103 and has fallen 84.4% since, to $1,106 in 2025. Among obstetrics & gynecology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $43.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Galderma Laboratories, L.p.$660
- Mayne Pharma Commercial LLC$443
- Therapeuticsmd, Inc.$408
- Astellas Pharma US Inc$335
- Novo Nordisk$323
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$6,80155%
- Food & beverage$5,37244%
- Education$1421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $7,825 |
| Galderma Laboratories, L.p. | 15 | $660 |
| Mayne Pharma Commercial LLC | 26 | $443 |
| Therapeuticsmd, Inc. | 24 | $408 |
| Astellas Pharma US Inc | 13 | $335 |
| Novo Nordisk | 17 | $323 |
| Mylan Pharmaceuticals Inc. | 7 | $151 |
| Sumitomo Pharma America, Inc. | 8 | $150 |
| Agile Therapeutics, Inc. | 9 | $143 |
| Revance Therapeutics, Inc. | 3 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $127 |
| Aspira Women's Health Inc | 3 | $125 |
| Amgen | 7 | $123 |
| Shield Therapeutics Inc | 7 | $123 |
| Scynexis, Inc. | 6 | $122 |
| Hologic Sales And Service, LLC | 6 | $122 |
| Merz North America, Inc. | 2 | $94 |
| Exeltis, USA Inc. | 5 | $93 |
| Vivus LLC | 5 | $80 |
| Pfizer | 4 | $77 |
| Daiichi Sankyo Inc. | 4 | $74 |
| Urovant Sciences Inc | 3 | $67 |
| Exact Sciences | 4 | $62 |
| Organon | 4 | $52 |
| Roche Diagnostics Corporation | 2 | $47 |
| Lilly USA, LLC | 2 | $42 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| AMAG Pharmaceuticals, Inc. | 2 | $42 |
| Myovant Sciences Inc. | 2 | $36 |
| Lupin Inc. | 2 | $33 |
| Axonics, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Minerva Surgical, Inc | 1 | $20 |
| Bayer | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Millicent US Inc | 1 | $17 |
| LSI Solutions Inc | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$12,314 in reported general payments places this provider in the 95th percentile of 673 obstetrics & gynecology providers in South Carolina.
See all obstetrics & gynecology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $108,115 |
| GemtesaVibegron | 58 | $55,125 |
| Estradiol | 318 | $23,134 |
| PremarinEstrogens, Conjugated | 44 | $20,263 |
| EstringEstradiol | 20 | $10,176 |
| ImvexxyEstradiol | 23 | $6,730 |
| ProgesteroneProgesterone, Micronized | 168 | $4,550 |
| Estradiol (Twice Weekly)Estradiol | 28 | $3,100 |
| YuvafemEstradiol | 13 | $3,066 |
| Metronidazole | 159 | $2,906 |
| ValacyclovirValacyclovir Hcl | 72 | $2,635 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 22 | $2,350 |
| Raloxifene Hcl | 36 | $2,211 |
| Moxifloxacin Hcl | 33 | $899 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 24 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $42 | $108,11585 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $150 | $55,12558 claims |
| PfizerPremarin, Estring | $77 | $30,43964 claims |
| Therapeuticsmd, Inc.Imvexxy | $408 | $6,73023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 673 obstetrics & gynecology providers in South Carolina.
Other obstetrics & gynecology in Bluffton
- Christopher JenningsAnderson$1.3M
- William ColemanGreenville$242K
- Melvin SeidMauldin$235K
- Brooke NaffzigerWest Columbia$70K
- Judith BurgisColumbia$59K
- Charis ChambersGreenville$46K
- Angela ChoiCharleston$43K
- Andrew FuttermanCharleston$38K
- William OttingerCharleston$35K
- Cristian ThomaeCharleston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.